Stock Research for DCTH


Featured Broker: Ally Invest

Get the due diligence for another stock.


DCTH Stock Chart & Research Data

The DCTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DCTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


DCTH Due diligence Resources & Stock Charts

The DCTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DCTH Detailed Price Forecast - CNN Money CNN View DCTH Detailed Summary - Google Finance
Yahoo View DCTH Detailed Summary - Yahoo! Finance Zacks View DCTH Stock Research & Analysis -

Stock Analysis

TradeIdeas View DCTH Trends & Analysis - Trade-Ideas Barrons View DCTH Major Holders - Barrons
NASDAQ View DCTH Call Transcripts - NASDAQ Seeking View DCTH Breaking News & Analysis - Seeking Alpha
Spotlight View DCTH Annual Report - OTC Report View DCTH OTC Short Report -
TradeKing View DCTH Fundamentals - TradeKing Charts View DCTH SEC Filings - Bar Chart
WSJ View Historical Prices for DCTH - The WSJ Morningstar View Performance/Total Return for DCTH - Morningstar
MarketWatch View the Analyst Estimates for DCTH - MarketWatch CNBC View the Earnings History for DCTH - CNBC
StockMarketWatch View the DCTH Earnings - StockMarketWatch MacroAxis View DCTH Buy or Sell Recommendations - MacroAxis
Bullish View the DCTH Bullish Patterns - American Bulls Short Pains View DCTH Short Pain Metrics -

Social Media Mentions

StockTwits View DCTH Stock Mentions - StockTwits PennyStocks View DCTH Stock Mentions - PennyStockTweets
Twitter View DCTH Stock Mentions - Twitter Invest Hub View DCTH Investment Forum News - Investor Hub
Yahoo View DCTH Stock Mentions - Yahoo! Message Board Seeking Alpha View DCTH Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for DCTH - Insider Cow View Insider Transactions for DCTH - Insider Cow
CNBC View DCTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DCTH - OTC Markets
Yahoo View Insider Transactions for DCTH - Yahoo! Finance NASDAQ View Institutional Holdings for DCTH - NASDAQ

Stock Charts

FinViz View DCTH Stock Insight & Charts - StockCharts View DCTH Investment Charts -
BarChart View DCTH Stock Overview & Charts - BarChart Trading View View DCTH User Generated Charts - Trading View

Latest Financial News for DCTH

Delcath Systems to Present at the 8th Annual LD Micro Invitational
Posted on Tuesday May 29, 2018

Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 12:00pm PST / 3:00pm EST. Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems, will be presenting and meeting with investors. Dr. Simpson’s presentation will be webcast live on the internet and can be accessed by visiting the News and Events section of the Company’s website at

Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event
Posted on Tuesday May 22, 2018

Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event.  A Cure in Sight is a patient advocacy group dedicated to providing patient services for ocular melanoma patients and their families. Looking for a Cure was held in Palo Alto, CA at the Byers Eye Institute on May 20, 2018. The event raised over $15,000 to support A Cure In Sight’s efforts in research, awareness and financial support programs for ocular melanoma patients.

Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases
Posted on Wednesday May 16, 2018

Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath’s CHEMOSAT® in the German national treatment guidelines for liver metastases from melanoma. This inclusion of treatment with CHEMOSAT is in the S3 Guidelines, which represents the highest level within the classification of the guidelines indicating that it is based on evidence and consensus within the German clinical community. The GGPO’s update was based on its evaluation of published data on treatment with CHEMOSAT as a loco-regional treatment for melanoma liver metastases.  Following this evaluation, and after soliciting additional feedback from the oncology community in Germany, treatment with CHEMOSAT was classified with Evidence Level 1B, indicating the second highest level of evidence.

Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 
Posted on Monday May 14, 2018

Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP Therapy was featured in a Video Learning Session presented at the Annual Meeting of the European Conference of Interventional Oncology (ECIO). Dr. M.C. Burgmans of Leiden University Medical Center (LUMC) in the Netherlands presented the training in the main auditorium session dedicated to advances in liver cancer therapies.  Dr. Burgmans presented an overview of the Percutaneous Hepatic Perfusion (PHP) procedure, discussed the therapy’s developmental history, demonstrating how to perform the procedure, as well as outlining its potential in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, and highlighting ongoing clinical research.

Enter a stock symbol to view the stock details.